AveXis Competitors, Revenue, Alternatives and Pricing
Estimated Revenue & Financials
- AveXis's estimated annual revenue is currently $211.3M per year.
- AveXis received $460.0M in venture funding in January 2018.
- AveXis's estimated revenue per employee is $155,000
- AveXis's total funding is $170.5M.
- AveXis has 1363 Employees.
- AveXis grew their employee count by 147% last year.
- AveXis currently has 1 job openings.
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Online Review||Pricing|
|Heidolph North ...||$10.1M||65||16%||N/A||-||N/A|
What Is AveXis?
AveXis, Inc., a Novartis Company, is a clinical-stage gene therapy company, dedicated to developing and commercializing novel treatments for patients suffering from rare and life-threatening neurological genetic diseases. Our initial product candidate, AVXS-101, is our proprietary gene therapy product candidate currently in development for the treatment of spinal muscular atrophy, or SMA, Type 1, the leading genetic cause of infant mortality, and for the treatment of SMA Type 2. The U.S. Food and Drug Administration, or FDA, has granted AVXS-101 Orphan Drug Designation for the treatment of all types of SMA and Breakthrough Therapy Designation, as well as Fast Track Designation for the treatment of SMA Type 1. In addition to developing AVXS-101 to treat SMA Type 1 and Type 2, we also plan to develop other novel treatments for rare neurological diseases, including Rett syndrome (RTT) and a genetic form of amyotrophic lateral sclerosis (ALS) caused by mutations in the superoxide dismutase 1 (SOD1) gene. How to reach us: AveXis, Inc. 2275 Half Day Road, Suite 200 Bannockburn, IL 60015 Email: email@example.com Office Phone: 847.572.8280 Toll-free Phone: 844.4.AVEXIS (844.428.3947)keywords:Biotechnology,Healthcare,Pharmaceuticals
Number of Employees
Employee Growth %
High-profile departures at Avexis raise more questions about Novartis's acquisition, but there were plenty of red flags before the deal was ...
In a statement, former AveXis chief scientific officer Brian Kaspar said he "categorically denies any wrongdoing" in the Zolgensma data scandal.
The global market for Spinal Muscular Atrophy Medicine has been analyzed in an in-depth market research report recently added to the rapidly ...
|2014-04-24||$Undisclosed||Undisclosed||PBM Capital Group||Article|
|2015-09-10||$65.0M||D||T. Rowe Price Associates||Article|
|2017-06-21||$230.0M||Undisclosed||Goldman Sachs & Co. LLC||Article|
|2018-01-17||$460.0M||Undisclosed||Goldman Sachs & Co. LLC||Article|
AveXis Executive Hires
|2015-06-19||Sean P. Nolan||Chief Executive Officer||Article|
|2016-07-12||Michael B. Johannesen||SVP General Counsel & Chief Compliance Officer||Article|
|2017-02-16||Rick Modi||SVP/Chief Business Officer||Article|
AveXis New Location/Offices
AveXis Hiring Plans
|Date||Number of Employees||Location||Reference|